Literature DB >> 25805536

Power of national economy, disease control and employment status in patients with RA-an analytical multi-site ecological study.

Herwig Pieringer1,2, Rudolf Puchner3, Erich Pohanka4, Kathrin Danninger5.   

Abstract

In rheumatology, sufficient disease control is a central part of the treatment concept. However, modern treatment strategies are associated with a substantial economic burden for health care systems. Ecological studies offer the unique opportunity to analyse differences between groups as well as group level effects. In the present analytical multi-site ecological study, we investigated whether more powerful national economies as measured by the gross domestic product per capita (GDPpc) are associated with better disease control in RA patients as measured by the disease activity score 28 (DAS28). We used aggregated data on RA patients from the recently published COMORA study as well as the World Health Organization database. There was a strong negative correlation between DAS28 and GDPpc (r = -0.815; p = 0.0002). Adjustment for sex, smoking status, disease duration or current employment status did not significantly change this association. There was a strong, negative correlation between DAS28 and age (r = -0.870; p < 0.001) and a strong, positive correlation between GDPpc and age (r = 0.737; p = 0.002). Adjustment for age reduced the regression coefficient (DAS28/GDPpc) to -0.000018 (p = 0.054). There was a negative correlation between DAS28 and current employment status (r = -0.642; p = 0.008) and a positive correlation between GDPpc and employment status (r = 0.722; p = 0.002). In conclusion, there is evidence of an association between disease control and GDPpc. This association is alleviated after adjustment for age. Of note, in countries with higher GDPpc, a higher proportion of RA patients are currently employed. This is true despite the fact that RA patients in countries with higher GDPpc are also older.

Entities:  

Keywords:  Disease control; Ecological study; Gross domestic product; Rheumatoid arthritis

Mesh:

Year:  2015        PMID: 25805536     DOI: 10.1007/s10067-015-2918-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Looking back: rheumatoid arthritis--aetiology, occurrence and mortality.

Authors:  D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2005-12       Impact factor: 7.580

2.  Treat-to-target: rationale and strategies.

Authors:  Josef S Smolen
Journal:  Clin Exp Rheumatol       Date:  2012-10-18       Impact factor: 4.473

3.  Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease.

Authors:  K P Machold; T A Stamm; V P K Nell; S Pflugbeil; D Aletaha; G Steiner; M Uffmann; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2006-08-09       Impact factor: 7.580

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

Review 5.  Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.

Authors:  H Pieringer; M Pichler
Journal:  QJM       Date:  2010-11-10

6.  Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Authors:  Anna-Birgitte Aga; Elisabeth Lie; Till Uhlig; Inge Christoffer Olsen; Ada Wierød; Synøve Kalstad; Erik Rødevand; Knut Mikkelsen; Tore K Kvien; Espen A Haavardsholm
Journal:  Ann Rheum Dis       Date:  2013-11-27       Impact factor: 19.103

7.  Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease.

Authors:  H A Fuchs; J J Kaye; L F Callahan; E P Nance; T Pincus
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

8.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

9.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

10.  Evolution of cost structures in rheumatoid arthritis over the past decade.

Authors:  Dörte Huscher; Thomas Mittendorf; Ulrich von Hinüber; Ina Kötter; Guido Hoese; Andrea Pfäfflin; Sascha Bischoff; Angela Zink
Journal:  Ann Rheum Dis       Date:  2014-01-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.